Y. Honda-Okubo

发表

Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single–dose influenza vaccine protection

N. Petrovsky, Y. Honda-Okubo, C. Ong, 2015, Vaccine.

Serological responses following influenza A H1N1 2009 infection in adults.

N. Petrovsky, Y. Honda-Okubo, D. Gordon, 2011, The Journal of infection.

Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology

N. Petrovsky, D. Barnard, C. Tseng, 2014, Journal of Virology.

A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.

N. Petrovsky, F. Saadé, Y. Honda-Okubo, 2013, Vaccine.

Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant

N. Petrovsky, D. Barnard, M. Cox, 2015, Methods in molecular biology.

Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study

B. Koczwara, C. Karapetis, G. Kichenadasse, 2020, Supportive Care in Cancer.

Influenza immunization during pregnancy: Benefits for mother and infant

N. Petrovsky, Y. Honda-Okubo, Isaac G. Sakala, 2016, Human vaccines & immunotherapeutics.

BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant

N. Petrovsky, Varun Khanna, D. Salunke, 2020, Human vaccines & immunotherapeutics.

Accelerated vaccine induction of IgM neutralising antibody enables vaccine protection against same day lethal influenza virus challenge

N. Petrovsky, Y. Honda-Okubo, Lei Li, 2021, bioRxiv.

Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.

N. Petrovsky, F. Saadé, Y. Honda-Okubo, 2012, Vaccine.

A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization.

N. Petrovsky, Y. Honda-Okubo, Isaac G. Sakala, 2021, Vaccine.

An Advax-adjuvanted Inactivated Cell-culture Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-flavivirus Antibodies and T-cell Immunity and Provides Single Dose Protection

N. Petrovsky, T. Komiya, Y. Honda-Okubo, 2021 .

A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle

N. Petrovsky, D. Sajkov, Y. Honda-Okubo, 2013 .

An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection

N. Petrovsky, T. Komiya, Y. Honda-Okubo, 2021, Vaccines.

Combined delivery of TLR2 and TLR7 agonists by Nanostructured Lipid Carriers Induces Potent Vaccine Adjuvant Activity in Mice.

S. K. Mehta, N. Petrovsky, D. Salunke, 2021, International journal of pharmaceutics.

Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective

N. Petrovsky, Y. Honda-Okubo, Isaac G. Sakala, 2021, Bioanalysis.

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Nikolai Petrovsky, Manon M J Cox, N. Petrovsky, 2012, Vaccine.

Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines

H. Yamada, C. Coban, K. Ishii, 2016, EBioMedicine.

A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.

N. Petrovsky, K. Killeen, Y. Honda-Okubo, 2022, Vaccine.

Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection

N. Petrovsky, T. Ross, S. Turville, 2021, bioRxiv.

Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant

N. Petrovsky, I. Barr, M. Aban, 2016, Vaccine.

A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.

N. Petrovsky, A. Kolpe, Y. Honda-Okubo, 2014, Vaccine.

Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy

M. Wiese, N. Petrovsky, R. Heddle, 2019, Journal of Pharmaceutical and Biomedical Analysis.

Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine

N. Petrovsky, D. Sajkov, Y. Honda-Okubo, 2015, PloS one.

An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects Cynomolgus macaques from a homologous SARS-CoV-2 virus challenge

N. Petrovsky, T. Ross, E. Howerth, 2023, Vaccine.

Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters

N. Petrovsky, H. Bielefeldt-Ohmann, R. Bowen, 2022, Vaccine.

Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine

N. Petrovsky, D. Sajkov, M. Cox, 2017, Human vaccines & immunotherapeutics.

Stereoisomeric Pam2CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants.

N. Petrovsky, D. Salunke, Y. Honda-Okubo, 2022, RSC medicinal chemistry.

Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines

N. Petrovsky, Y. Honda-Okubo, Jeremy Baldwin, 2021, Pathogens.

An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.

N. Petrovsky, B. Hurst, Y. Honda-Okubo, 2023, Vaccine.

Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants

N. Petrovsky, Y. Honda-Okubo, Hamidreza Kafi, 2023, Immunology.

Developmental and reproductive safety of Advax-CpG55.2™ adjuvanted COVID-19 and influenza vaccines in mice.

N. Petrovsky, Y. Honda-Okubo, Isaac G. Sakala, 2023, Vaccine.

An Advax-CpG55.2 adjuvanted recombinant hemagglutinin vaccine provides immunity against H7N9 influenza in adult and neonatal mice.

N. Petrovsky, B. Hurst, Y. Honda-Okubo, 2023, Vaccine.

An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge

N. Petrovsky, T. Ross, E. Howerth, 2023, Vaccine.

A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.

N. Petrovsky, M. Bäckström, T. Bergström, 2021, Vaccine.